Last quote about Monsanto
All quotes about Monsanto
We had no interaction with Monsanto at all during the process of reviewing the data and writing the papers.
I think it's important that people hold Monsanto accountable when they say one thing and it's completely contradicted by very frank internal documents.
We would be keeping the cost down by us doing the writing and they would just edit & sign their names so to speak.
When you go to SNL and Leslie pulls out reno plans to review. Any other cast renos I can help with? How about a meditation room for Vanessa [Bayer], karaoke studio for Kenan [Thompson] and a karate dojo for Kate [McKinnon]?
Hakan will be [under contract] at Leverkusen for three years. If an offer comes along that is fine for Bayer and which also fits with Hakan, we will do a transfer. But the final decision lies with the club.
The fact that with the combination of both companies' competencies, we can develop better solutions faster, that will provide benefits to farmers and people in the world, by providing affordable and safe food for an ever-growing population.
We price our drugs in line with their innovation potential and in line with the competitive environment. I think even more importantly, President Trump could develop a better understanding of the overall health care market, the industry and what is driving cost up really. If you look at pharmaceutical pricing - as a total share of health care funding it actually has not changed since the early 1960s and has been very stable around 10 percent. The combination of Bayer's crop business and Monsanto's business is actually all about innovation.
We have said we plan to fully divest the stake over the medium term, without speaking about the modalities. As to how that will play out, there are many ways. Covestro is a highly attractive company and that is now also reflected in the market value.
We have tissue culture experiments that demonstrate that it's antiviral. It's all friends and family at this point.
One of the things that happens during the processing is they bleed out. So it's not that different than the normal process. There are massive amounts of blood you're (processors) paying sewer charges on.
What makes us unique is that we can collect millions of pounds of [lobster serum]. That is something – the serum – that's currently going down the drain.
I thought I had said goodbye, but the pull of fate is undeniable. So, I must return. I must find the strength to ... I've got the slicked back hair, I'm a little old for that, but yeah. Because I'd just have to sit there and go, Duh.'.
I'm trying to be patient in the first – not 100 days – but the first couple hundred days. But I just wish President Trump would give us a reason to feel good and to feel safe and to feel like he's representing our interests. I want him to succeed, but I think that his definition of success is going to be very different than mine.
Oh, it's a big deal.
It's going to take a long while for all the evidence to be presented. I think we're talking years. But there's no magic wand to do that. We made a mistake; it's just that simple. For 18 years we didn't explain (to the consumer) what is biotechnology, what's it for and why it's safe.
This is a new reality for Novozymes.
There's a risk that the huge focus Monsanto has had on biological solutions will be less at Bayer. That's not our expectation, but we don't know until the transaction is finalised.
My sense is that even if they remove the entire legislation on bioethanol, consumption in the United States will still be high, although probably a little less that today.
Even though they're doing similar work, Syngenta, Monsanto Dow and Pioneer are all competitors, and they're trying to keep the millions of dollars that they've put in to research the genetics lines that they're developing as confidential business information. You're basically limiting somebody's use of their private property, without just cause if you don't have the science to back up what you're asking for.
Powerful moves can, and often do, elude those who are only focused on the underlying companies and not the action of the stocks themselves.
When you spot these highly unusual moves you may be able to strap yourself into a real moon shot.
We are willing to negotiate an extension of the time frame.
The three years proposed by the government is not adequate because it takes longer to develop new seed varieties.
The time during which royalties have to be paid will have to be negotiated in a way that works for both the seed industry and the farmers. The good news is that now both parties are willing to negotiate.
I think those augur well for the deal.
Accessing cell-based therapies is part of Bayer's strategy. We are launching this enterprise to develop transformative and curative therapies for patients based on the latest stem cell technology.
They just wanted to make sure you weren't having some farmer just go to a bin (of genetically modified seeds) and plant whatever he wanted. Other than that, they were fine with the program.
There is no such pricing in place yet.
Bayer despises that we're doing it. We are constantly changing things to fit what Bayer wants.
It just ticks them off.
PCBs sold at the time were a lawful and useful product that was then incorporated by third parties into other useful products. If improper disposal or other improper uses created the necessity for clean-up costs, then these other third parties would bear responsibility for these costs.
Market participants are trying to assess the impact of the Trump's victory. But I expect rotation from low volatility sectors such as utilities into banks or tech companies to continue until the end of the year.
The 300-400 basis points premium on the average of other deals is high ... makes the Monsanto takeover even more value destroying and might mirror the insecurity on the deal and the pending capital raise.
Piling on more pesticides will just result in superweeds resistant to more pesticides.
Prices on crops have fallen, which makes many farmers not invest in long-term solutions (for their crops) and only buy the grains instead of the technology that we offer.
It looks like the positive development in China has been underestimated.
I think it is likely and we are expecting it, but it is not certain. The process was going along and then on Sept. 14 ... the Bayer and Monsanto deal was announced, since then in both the U.S. and the EU there has been a very large escalation in data requests and questions.
Be assured that Bayer will have a unified croporate culture.
If they say, we're going to keep it all for ourselves,' that would hurt us.
It's the big question that everybody is looking at right now. Anything that does not support the expansion of the licensing market, we are against.
Especially in agriculture, innovation is a requirement not a choice.
They are competitors, yes.
This transaction will increase competition in seeds and traits.
"Farmers don't want to lock into any particular combination of seeds and crop chemical at an early stage". "You can sell the two in the bundle, but only if you happen to have the best product in each category. Not even the biggest companies could secure such a dominant position".
Consolidation in the industry is a prerequisite to further investment in R&D.
Farmers don't want to lock into any particular combination of seeds and crop chemical at an early stage. You can sell the two in the bundle, but only if you happen to have the best product in each category. Not even the biggest companies could secure such a dominant position.
It will ... create an innovation engine for the next generation of farming.
This merger is not a slam dunk.
The transaction has the potential to result in a significant loss of competition and reduced incentives and ability to innovate, thereby raising prices.
These mergers boost the profits of huge corporations and leave Americans paying even higher prices.
People don't get the enormous impact that these deals can have on innovation markets. You need more innovators in there battling it out so that you actually do produce new technology for farmers.
I would have to say this: I think there will be some concern from the growers because of the consolidation.
My view on the market is that it's going to be pretty flat, possibly down, over the next few days while they wait for yet another ... macro-statistical event to come out.
Given recent updates on the Monsanto approach suggest a final conclusion may be close, we suspect (Bayer) will work hard to try and reach a final conclusion before the Meet Management event, if possible.
The company will be left with a highly geared balance sheet and the management effort to integrate the two businesses could easily lead to the larger pharmaceutical business being neglected.
Company employees are in unique positions behind-the-scenes to unravel complex or deeply buried wrongdoing. Without this whistleblower's courage, information, and assistance, it would have been extremely difficult for law enforcement to discover this securities fraud on its own.
Despite the whitefly attack, farmers in northern India are still interested in cotton, but they are moving to the desi (indigenous) variety.
Just wait for the crucial three to four years to see a complete, natural turnaround. By then most farmers will give up Bt cotton and go for the indigenous variety.
I am happy that the new offer made by Bayer did not go as far as $135-$140. However I don't think it will be enough -- Monsanto management rejected the $122 offer as financially inadequate.
He "could see a little extra motivation to do something with Monsanto because the eventual commercialization of seeds with the Dicambra tolerance trait.
They are under pressure to start delivering on promises, and it's been a long time since they've done that.
By engaging in conversations with BASF, the message to Bayer is you either have to give us a better price or we may consider doing something with BASF. I don't think they believe selling for $125 (per share) today is in the best interests of shareholders... and I do believe they are still considering being a consolidator and not a consolidee.
We are convinced that this transaction is the best opportunity available to provide Monsanto shareholders with highly attractive, immediate and certain value. Bayer is fully committed to pursuing this transaction.
We want to foster new startups in the agricultural sector. There is a vast area for research and development.
Our evaluation was a review of all the published scientific literature on glyphosate and this was done by the world's best experts on the topic that in addition don't have any conflicts of interest that could bias their assessment, and they concluded that, yes, glyphosate is probably carcinogenic to humans based on three strings of evidence, that is clear evidence of cancer in experimental animals, limited evidence for cancer for humans from real-world exposures, of exposed farmers, and also strong evidence that it can damage the genes from any kind of other toxicological studies.
It is an important topic that needs important scrutiny, yes.
I think it's important to understand the literature that our assessment that glyphosate can cause cancer in humans still stands, and then you have to look at the other assessments for the specific scenarios, and that is not my authority to comment on these evaluations.
Our classification of the cancer hazards of glyphosate still stand. We are the authority to classify cancer substances worldwide for the WHO, and it was then this other panel that looked at a very narrow angle of exposure from daily food, and then came up with the conclusion on how much of that may be safe or not.
This is really an independent review of all the published literature that then leads to a classification about what we know about the substance and particularly its cancer-causing effects, but then it's up to other agencies, the WHO internationally or other national agencies to turn that into a risk assessment and decide on the different exposures in our use, for farmers, from our diet, in cosmetics, wherever the substance can end up, to come up with conclusions.
It happened shortly before the rapeseed colza harvest. In our region the colza is sprayed to death. My animals were harmed because at the very moment the colza was treated with glyphosate, they were exposed to the toxic mist. They got cramps, they got diarrhoea, they died within days.
There is just ten meters between the property line and the enclosure for my dogs. It is unavoidable that the wind carries glyphosate to us… We cannot do anything. She had been operated on the lower milk line to remove tumours, but they came back. Two of them you can see: cancer is growing there… and there. Four tumours on the same milk line.
Have a look yourself: this is my hayfield, some 16 to 17 hectares. It is surrounded by cornfields treated with herbicides.
Well, glyphosate – such as Roundup and other brands – is sold almost everywhere. You can buy it without difficulty.
Once you start digging into this story, you'll get a kind of feeling that all this is not just about science – but about politics. So, let's have a talk with the politicians….
Well, looks impressive… A field not sprayed with glyphosate and it's a sheer riot of colours.
Over the past several weeks, with the support of our board and advisors, I have personally been in discussions with Bayer's management regarding this proposal, along with others regarding other strategic alternatives.
We encountered several headwinds in the quarter. These included the expected absence of last year's Scotts licensing agreements and the anticipated glyphosate pricing declines.
The combination of weak results and a weaker-than-expected outlook suggests a more conciliatory tone will be taken to merger proposals. We expect a modestly better proposal (e.g. break-up fee, antitrust tactics) before Monsanto's annual meeting.
In our view, a Bayer/Monsanto combination helps to ensure the new company will remain a leader among a changing [agribusiness] backdrop with a more formidable competitor in Dow/DuPont and likely market disruption from the potential Syngenta/ChemChina combination.
For antitrust purposes, we expect that Bayer will have to divest seed crossover, which would be primarily cotton, canola and some vegetables. Assuming that BASF is the stand-alone ... [agribusiness] major at the end of this consolidation wave, we believe BASF (a chemical producer based in Germany) would potentially be a leading strategic buyer of the divested seed assets given its historical intent to purchase a seed business.
Bayer have backed themselves into a corner. The money would have been better spent buying their own stock. Alas, for shareholders, it was not to be.
With this decision all they do is cast doubt on that system, and create fear and confusion amongst Europe's consumers.
Extending the glyphosate licence would be like smelling gas and refusing to evacuate to check for a leak. As long as there is no meaningful EU-wide restriction on glyphosate use, we will continue to live in a world that is awash in a weedkiller which is a likely cause of cancer.
The opportunity to use data in meaningful and new ways means that we need new and different types of skills and competences to drive agriculture technology forward.
That partnership shows up as an opportunity to create an annual development program where selected students join us at our world's headquarters and spend time with us learning about the agro business broadly, but also preparing for future careers.
Some of the most difficult-to-fill positions tend to be software engineers. The competition is vast. Everyone is looking for data scientists, those are people who not only understand data but have the ability to translate it into commercial insights for farmers, and the third would be cybersecurity.
We believe in the substantial benefits an integrated strategy could provide to growers and broader society, and we have long respected Bayer's business. However, the current proposal significantly undervalues our company and also does not adequately address or provide reassurance for some of the potential financing and regulatory execution risks related to the acquisition.
We are not feeding Peter by starving Paul here.
We fully expect a positive answer of the Monsanto board of directors.
We are putting forward a very, very full price.
The price that has now been disclosed is at the upper limit and it is just about economical. Should it rise further, which is to be assumed, the takeover will become increasingly unattractive.
It is clear that the Fed is ready to move again soon. And if expectations of a June hike continue to build, the Fed may well take the opportunity to take another step towards normalization next month without fear of surprising the markets.
While the leverage appears to be manageable from a (credit) ratings perspective, we believe that it would curtail Bayer's strategic flexibility in the Healthcare space.
After a Monsanto deal it can largely be ruled out for Bayer to retain the financial flexibility over the next two to three years for acquisitions in the pharma market.
I had hoped that the days of such arrogant empire-building and ignorance of the actual owners of the business were at an end.
Bayer's pharma business is in excellent health today, but the clock is ticking regarding rebuilding its pipeline and recent newsflow has been disappointing.
This is no surprise, since the commission has continued to ignore the concerns of independent scientists, [EU lawmakers] and European citizens.
A combination of both companies would create $67 billion of annual sales and the world's largest seed and crop-chemical company. However, the question is if Monsanto would be interested in a deal.
It's all wild speculation because there's nothing there.
It's proven that glyphosate has negative effects on the environment. That needs to be fully taken into account for the approval. Given that there is still uncertainty about the health risks associated with glyphosate, the SPD-led ministries will not agree to the approval of glyphosate.
It is scandalous that the Commission is ramming through an EU approval for glyphosate to be used with no restrictions, despite the very serious concerns about the impact of this toxic substance on public health and the environment. Clearly banning glyphosate would be the responsible course of action.
India is too huge a seed market for anyone to leave (of) one's own choice.
We sincerely hope that the government will be fair in its approach and that certain reports in the public domain are false... It is difficult for MMBL to justify bringing new technologies into India in an environment where such arbitrary and innovation stifling government interventions make it impossible to recoup research and development investments focused on delivering extensive farmer benefits and where sanctity of contracts is absent.
If the committee recommends imposing a sharp, mandatory cut in the trait fees paid on Bt-cotton seeds, MMB will have no choice but to re-evaluate every aspect of our position in India. It is difficult for MMB to justify bringing new technologies into India in an environment where such arbitrary and innovation stifling government interventions make it impossible to recoup research and development investments.
The FDA unacceptably puts patients at risk by allowing the device to continue to be marketed as this surveillance study proceeds.
We feel very comfortable with what we have. We are very disciplined in our approach. You have to answer the question how do you create value for your shareholders and you have to look at multiples and price expectations.
The outlook is conservative in the context of the CEO handover. The intention was arguably not to burden the successor with too ambitious targets, but the outlook is below our estimates and below consensus.
We are working hard on our savings programme. We will be able to show margin improvement this year, perhaps as the only one in the sector.
A combination with DuPont would have made a lot of sense for us, but unfortunately that is off the table now.
Things are moving. Something can happen at any time.
An offer price has to be measured against our share price without any latent takeover fantasies. And I believe such a price would be closer to our ideas.
China is a serious partner and has to be taken into consideration. The Chinese have made big takeovers in the West, mostly successful, as the examples of Volvo and Lenovo show. We view ChemChina with the same seriousness as Monsanto, Bayer or BASF.
I believe that this is an appropriate time for the company to benefit from the perspectives of a new leader.
I wish John every success in his new role.
If a woman gets pregnant during the period of crop fertilization, the risk is very high that she will have a disabled baby.
The economic tailwind from the last two years is clearly fading away.
When you search for the reasons for Germany's economic strength, you might think of the big names of her industrial history like Bayer or Porsche, Thyssen-Krupp or Siemens; you might think of regions like the Ruhr, Hamburg, Rhein-Main (Frankfurt) or Stuttgart. But we found the answers somewhere else.
For Monsanto, there was no evidence of a causal link between the symptoms presented by Mr. Francois and the inhalation of a weedkiller.
Therefore these tests give no real information about the effects of genetically modified food on health over a lifetime.
There should be no GMO's in our fields, and the ruling confirms this. It encourages us to continue to influence the political debate and eliminate GMO's from agriculture.
If this is proved and based on sound scientific evidence then the European Commission will obviously act accordingly.
There is no clearly defined data analysis and it would appear the authors have gone on a statistical fishing trip.
Paris Saint-Germain luckily avoided the two unseeded English heavyweights City and Arsenal and will play against a more welcomed opponent in Bayer Leverkusen who are already labeled as the underdogs. But, second in the Bundesliga this season behind Bayern Munich, they are underdogs with huge potential for causing an upset.